Level Four Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
VCM
N
Level Four Advisory Services's REGN Position: Q1 2026 in Review
Level Four Advisory Services reduced its Regeneron Pharmaceuticals (REGN) stake by 6% in Q1 2026, selling an estimated $43.6K and leaving 895 shares worth $692K. The position accounts for 0.02% of the portfolio, ranked #507.
Level Four Advisory Services first reported a position in REGN in Q2 2021 and has held it in 11 quarters since. The position peaked at $2.05M in Q2 2021. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Level Four Advisory Services held 895 shares of Regeneron Pharmaceuticals worth $692K as of Q1 2026.
- Level Four Advisory Services sold 57 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $43.6K.
- Regeneron Pharmaceuticals made up 0.02% of Level Four Advisory Services's portfolio in Q1 2026, its #507 holding.
- Level Four Advisory Services first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
- Level Four Advisory Services's Regeneron Pharmaceuticals position peaked at $2.05M in Q2 2021.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.